445 related articles for article (PubMed ID: 11135090)
1. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
2. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
3. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.
Kim YL; Do J; Park SH; Cho K; Park J; Yoon K; Cho DK; Lee EG; Kim IS
Nephrology (Carlton); 2003 Oct; 8 Suppl():S28-32. PubMed ID: 15012688
[TBL] [Abstract][Full Text] [Related]
4. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
5. Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis.
Rippe B; Simonsen O; Wieslander A; Landgren C
Perit Dial Int; 1997; 17(1):27-34. PubMed ID: 9068019
[TBL] [Abstract][Full Text] [Related]
6. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
7. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
8. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
9. Overnight mesothelial cell exfoliation: a magic tool for predicting future ultrafiltration failure in patients on continuous ambulatory peritoneal dialysis.
Kanjanabuch T; Siribamrungwong M; Khunprakant R; Kanjanabuch S; Jeungsmarn P; Achavanuntakul B; Pongpirul K; Park MS; Tungsanga K; Eiam-Ong S
Perit Dial Int; 2008 Jun; 28 Suppl 3():S107-13. PubMed ID: 18552238
[TBL] [Abstract][Full Text] [Related]
10. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag.
Cappelli G; Bandiani G; Cancarini GC; Feriani M; Dell'Aquila R; Saffioti S; Spisni C; Stingone A; Orazi E; Ballocchi S; Renaux JL
Adv Perit Dial; 1999; 15():238-42. PubMed ID: 10682110
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
12. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
[TBL] [Abstract][Full Text] [Related]
13. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid.
Simonsen O; Wieslander A; Landgren C; Rippe B
Adv Perit Dial; 1996; 12():156-60. PubMed ID: 8865892
[TBL] [Abstract][Full Text] [Related]
14. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
[TBL] [Abstract][Full Text] [Related]
15. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
Fusshoeller A; Plail M; Grabensee B; Plum J
Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
[TBL] [Abstract][Full Text] [Related]
17. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD.
Pannekeet MM; Zemel D; Koomen GC; Struijk DG; Krediet RT
Perit Dial Int; 1995; 15(6):217-25. PubMed ID: 7578497
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.
Posthuma N; ter Wee PM; Donker AJ; Oe PL; Peers EM; Verbrugh HA
Perit Dial Int; 2000; 20 Suppl 2():S106-13. PubMed ID: 10911654
[TBL] [Abstract][Full Text] [Related]
19. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.
Jones S; Holmes CJ; Krediet RT; Mackenzie R; Faict D; Tranaeus A; Williams JD; Coles GA; Topley N;
Kidney Int; 2001 Apr; 59(4):1529-38. PubMed ID: 11260417
[TBL] [Abstract][Full Text] [Related]
20. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
